New Lung Cancer Drug Combination Could Cut Risk by 51%
A Phase III study found this combination therapy effectively reduced disease progression in patients with advanced lung cancer.
Updated on Oct. 25, 2026 in Cancer
Live Poll
Do you believe new pharmaceutical research typically leads to meaningful improvements in patient health?
A Phase III study of the drug combination sacituzumab tirumotecan plus pembrolizumab shows a significant reduction in disease progression for patients with advanced lung cancer. The trial results, which met their primary endpoint, offer a potential new pathway for those with specific driver gene-negative and PD-L1-negative lung cancers.
Why it matters
This combination therapy could change standard care for patients with difficult-to-treat non-squamous non-small cell lung cancer. The findings provide a new potential option for populations where current chemotherapy-based approaches may be less effective.
In a Phase III randomized trial of 455 patients, sacituzumab tirumotecan combined with pembrolizumab achieved a 51% reduction in the risk of disease progression or death compared to platinum-based chemotherapy. The study met its primary endpoint for progression-free survival using blinded independent review.
The players
Kelun-Biotech
A Chengdu-based pharmaceutical company specializing in the research and development of antibody-drug conjugates and novel cancer therapies.
MSD
A global biopharmaceutical company that produces pembrolizumab, a widely used immunotherapy for various cancers.
The details
The treatment involves an antibody-drug conjugate (ADC) designed to target and deliver therapy specifically to cancer cells while minimizing systemic impact. In this study, patients received this ADC paired with the immunotherapy drug pembrolizumab. The results also indicated that the treatment group experienced lower incidences of Grade 3 or higher adverse events than those receiving standard chemotherapy.
Timeline
May 2022: Kelun-Biotech licensed the rights to sacituzumab tirumotecan to MSD.
June 9, 2026: Data cut-off date for the OptiTROP-Lung06 trial.
October 25, 2026: Results presented at the ESMO Congress and published in The New England Journal of Medicine.
Health Landscape
The development follows a broader industry trend of integrating antibody-drug conjugates with immunotherapy to enhance outcomes in non-small cell lung cancer. This study adds to the growing body of evidence testing whether such combinations can surpass standard platinum-based chemotherapy.
This study highlights a developing option for those with specific driver gene-negative and PD-L1-negative lung cancer diagnoses. Patients should discuss with their oncology team whether clinical trials or emerging ADC-based therapies are relevant to their specific cancer profile.
The takeaway
Combination therapies utilizing antibody-drug conjugates continue to show promise in reducing disease progression for certain lung cancers. Patients and caregivers should maintain an open dialogue with their physicians about the evolution of these precision treatment options.
Further reading
For more information on current treatment trends, visit our Cancer section.
More information
Review the latest Kelun-Biotech company information regarding these clinical developments.
Live Poll
Do you believe new pharmaceutical research typically leads to meaningful improvements in patient health?
